SCHEMBL21553119

SCHEMBL21553119

CCOC(=O)CCc1cn(-c2ccc(-c3ncccn3)cc2)c(=O)c(N2CCN(C(=O)O)CC2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
HTR3A P46098 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
KMT2A Q03164 7/20 0.36
MEN1 O00255 6/20 0.36
KDM4E B2RXH2 4/20 0.36
MAPT P10636 4/20 0.36
ALDH1A1 P00352 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
GRM5 P41594 1/20 0.35
POLB P06746 2/20 0.35
ADRB2 P07550 1/20 0.35
FAAH O00519 1/20 0.35
TP53 P04637 2/20 0.35
METAP1 P53582 1/20 0.34
CCKAR P32238 1/20 0.34
NPC1 O15118 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21564622 0.91 MTOR (0.40) KMT2AMEN1KDM4EMAPTALDH1A1
SCHEMBL21564640 0.89 CKS1B (0.40) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL21564627 0.89 MTOR (0.44) LMNAHTT
SCHEMBL21564519 0.89 MAPK13 (0.40) KMT2AMEN1KDM4EMAPTALDH1A1
SCHEMBL21552853 0.86 GABRA2 (0.41) KMT2AMEN1KDM4EMAPTALDH1A1
SCHEMBL21552985 0.84 DGAT1 (0.36) KDM4EMAPTALDH1A1FAAHL3MBTL1
SCHEMBL21553110 0.84 SLC6A7 (0.36) ALDH1A1GRM5LMNAL3MBTL1
SCHEMBL21553067 0.83 DDX3X (0.37) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL21552964 0.83 PFKFB3 (0.38) KMT2AMEN1KDM4EMAPTALDH1A1
SCHEMBL21552906 0.82 L3MBTL1 (0.41) KMT2AMEN1KDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3790867-B1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2024-03-27 EP disclosed
US-11932629-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2024-03-19 US disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed
EP-3790867-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2021-03-17 EP disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11932629-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A HTR3E 3470/4885HTR3B 3305/4885HTR3A 3478/4885
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A HTR3E 3470/4885HTR3B 3305/4885HTR3A 3478/4885
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1A, KDM1B, KDM2A HTR3E 3780/4885HTR3B 3616/4885HTR3A 3527/4885
US-11578059-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A HTR3E 3470/4885HTR3B 3305/4885HTR3A 3478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.